share_log

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K: SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics | 8-K：SERA 預測報告了 2024 年第三季度財務業績
美股SEC公告 ·  2024/11/06 16:15

Moomoo AI 已提取核心訊息

Sera Prognostics reported Q3 2024 revenue of $29,000, down from $42,000 in Q3 2023. Operating expenses increased 8% to $8.9 million, with net loss widening to $7.9 million from $7.2 million YoY. R&D expenses remained stable at $3.5 million, while SG&A expenses rose to $5.4 million from $4.6 million.The company made significant progress in commercializing its PreTRM test, including launching a direct-to-consumer testing option with home sample collection in October 2024. Sera also initiated a nationwide awareness campaign featuring TV programs with Dennis Quaid and Meg Ryan, reaching over 84 million homes. The data analysis for the full PRIME study is underway, with publication expected in early 2025.Strategic improvements include transitioning to ambient whole blood collection, which has reduced costs and increased lab capacity. The company has strengthened its commercial team with key hires in sales and marketing, positioning itself for anticipated business growth following the publication of PRIME study results.
Sera Prognostics reported Q3 2024 revenue of $29,000, down from $42,000 in Q3 2023. Operating expenses increased 8% to $8.9 million, with net loss widening to $7.9 million from $7.2 million YoY. R&D expenses remained stable at $3.5 million, while SG&A expenses rose to $5.4 million from $4.6 million.The company made significant progress in commercializing its PreTRM test, including launching a direct-to-consumer testing option with home sample collection in October 2024. Sera also initiated a nationwide awareness campaign featuring TV programs with Dennis Quaid and Meg Ryan, reaching over 84 million homes. The data analysis for the full PRIME study is underway, with publication expected in early 2025.Strategic improvements include transitioning to ambient whole blood collection, which has reduced costs and increased lab capacity. The company has strengthened its commercial team with key hires in sales and marketing, positioning itself for anticipated business growth following the publication of PRIME study results.
Sera Prognostics報告2024年第三季度營業收入爲29,000美元，較2023年第三季度的42,000美元下降。營業費用增長8%，達890萬，淨虧損同比擴大至790萬，較720萬有所增加。研發費用保持穩定，爲350萬，而銷售、一般和行政費用從460萬上升至540萬。公司在商業化其PreTRm測試方面取得了重大進展，包括在2024年10月推出家庭樣本收集的直接面向消費者的測試選項。Sera還啓動了一項全國範圍的宣傳活動，通過電視節目與Dennis Quaid和Meg Ryan合作，覆蓋超過8400萬戶家庭。全PRIME研究的數據分析正在進行中，預計將在2025年初發表。戰略性改善包括轉向常溫全血採集，這降低了成本並增加了實驗室容量。公司在銷售和市場營銷方面通過關鍵人才的招聘來加強其商業團隊，爲預計在PRIME研究結果公佈後實現業務增長做好準備。
Sera Prognostics報告2024年第三季度營業收入爲29,000美元，較2023年第三季度的42,000美元下降。營業費用增長8%，達890萬，淨虧損同比擴大至790萬，較720萬有所增加。研發費用保持穩定，爲350萬，而銷售、一般和行政費用從460萬上升至540萬。公司在商業化其PreTRm測試方面取得了重大進展，包括在2024年10月推出家庭樣本收集的直接面向消費者的測試選項。Sera還啓動了一項全國範圍的宣傳活動，通過電視節目與Dennis Quaid和Meg Ryan合作，覆蓋超過8400萬戶家庭。全PRIME研究的數據分析正在進行中，預計將在2025年初發表。戰略性改善包括轉向常溫全血採集，這降低了成本並增加了實驗室容量。公司在銷售和市場營銷方面通過關鍵人才的招聘來加強其商業團隊，爲預計在PRIME研究結果公佈後實現業務增長做好準備。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Icecure Medical
    ICCM
    -- 1.495
    electroCore
    ECOR
    -- 18.7500
    Biomerica
    BMRA
    -- 0.893
    安特瑞斯科技
    AVR
    -- 8.590
    Rapid Micro Biosystems
    RPID
    -- 3.711
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！